APOLIPOPROTEIN-BASED LIPOPROTEIN SUBCLASS PROFILES AMP; VASC COMPLIC OF DIABETES

这个子项目是利用由NIH/NCRR资助的中心拨款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金，因此可能会出现在其他CRISE条目中。列出的机构是针对中心的，而不一定是针对调查员的机构。目的：探讨2型糖尿病患者和对照组载脂蛋白亚类分布及其与1型糖尿病视网膜病变(DR)的关系，以及他汀类药物在2型糖尿病中的作用。理论基础：血管并发症是糖尿病发病率和死亡率的主要原因。有证据表明，血脂异常会导致微血管和大血管并发症的风险。目前还没有关于1型糖尿病载脂蛋白定义的脂蛋白亚类与糖尿病视网膜病变的关系的报道，也没有关于常用降脂药物对2型糖尿病亚类的影响的报道。由于基于载脂蛋白的颗粒分析允许对复杂系统的新视角，这一提议将提供重要的新知识。假设：基于载脂蛋白的血浆脂蛋白亚类分布与糖尿病大血管和微血管并发症的发生有关，可能有助于识别血管并发症的高危患者。具体目标：(目标1)测定50例1型糖尿病患者(25例有糖尿病视网膜病变，25例无糖尿病视网膜病变)和对照组的载脂蛋白载脂蛋白谱，以确定与视网膜病变和糖尿病的关系；以及(目标2)50例2型糖尿病患者(25例服用他汀类药物，25例不服用他汀类药物)和健康对照组，并确定与他汀类药物消耗的相关性。目的：探讨1型和2型糖尿病患者载脂蛋白谱与其他脂蛋白特征(核磁共振、载脂蛋白A1、B和Lp(A)、常规脂蛋白谱)的关系。方法：从来我们糖尿病诊所就诊的患者队列中招募患者。载脂蛋白亚类测定和数据分析的所有方法都已到位。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Objectives: To investigate apolipoprotein-based lipoprotein subclass profiles in diabetic and control subjects and their associations with diabetic retinopathy (DR) in Type 1 diabetes and the effect of statins in Type 2 diabetes. Rationale: Vascular complications cause a majority of the morbidity and mortality of diabetes. Evidence suggests that dyslipidemia mediates risk for micro- and macro-vascular complications. There are no reports about the characterization of apolipoprotein-defined lipoprotein subclasses in Type 1 diabetes in relation to DR, and inadequate information about effects of commonly used lipid lowering drugs on subclasses in Type 2 diabetes. Since apolipoprotein-based particle analysis allows a new view of a complex system, this proposal will provide important new knowledge. Hypotheses: Apolipoprotein-based plasma lipoprotein subclass profiles are associated with the development of the macro- and micro-vascular complications of diabetes, and may help identify at-risk patients for vascular complications. Specific Aims: Determine apolipoprotein-based lipoprotein profile in (Aim 1) 50 type 1 diabetic patients (25 with DR, 25 without DR), and in control subjects to define associations with retinopathy and diabetes; and (Aim 2) in 50 type 2 diabetic patients (25 taking statins, 25 not taking statins), and healthy control subjects and to define associations with statin consumption. Aim 3: Investigate relationship between apolipoprotein-based profiles in type 1 and type 2 diabetic subjects and other lipoprotein characteristics (NMR, apoA1, B and Lp(a), conventional lipid profiles). Methods: Patients will be recruited from the patient cohort attending our diabetes clinics. All methods for apolipoprotein subclass determination and data analysis are in place.